📇 Rhumatologue · VILLAINES SOUS BOIS · (95) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
33 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
82.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
42
42 articles ont été cités au moins 42fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
7 577
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
289
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
96
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock
2022ArticleJAMA Network Open
On the origin of basal stacking faults in nonpolar wurtzite films epitaxially grown on sapphire substrates
2012ArticleJournal of Applied Physics
Thermal annealing of molecular beam epitaxy-grown InGaN/GaN single quantum well
2012ArticleSemiconductor Science and Technology
Picosecond Time-Resolved Cathodoluminescence to Probe Exciton Dynamics in GaN and GaN based heterostructures
2011CongrèsCathodo-luminescence 2011.
Picosecond Time-Resolved Cathodoluminescence to Probe Exciton Dynamics in a-Plane (Al,Ga)N/GaN Quantum Wells.
2011CongrèsMicroscopy and Microanalysis
One-dimensional exciton luminescence induced by extended defects in nonpolar GaN/(Al,Ga)N quantum wells.
2010ArticleSemiconductor Science and Technology
Exciton dynamics in a-plane (Al,Ga)N/GaN single quantum wells grown by molecular beam epitaxy on ELO-GaN.
2010CongrèsInternational Workshop on Nitride Semiconductors - IWN 2010
Novel Picosecond Time-Resolved Cathodoluminescence to Probe Exciton Recombination Dynamics in GaN and GaN Based Heterostructures.
2010CongrèsMicroscopy and Microanalysis (M&M) 2010
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR DENIS MARTIN
46 RUE DE LA GARE, 95570 VILLAINES SOUS BOIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2024
Arthritis & rheumatology (Hoboken, N.J.) · 2023
ObjectiveBrepocitinib is a TYK2/JAK1 inhibitor in development for the treatment of several immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in participants with moderately‐to‐severely active psoriatic arthritis (PsA) for up to 52 weeks.MethodsIn this placebo‐controlled, dose‐ranging, phase IIb study, participants were randomized to receive 10 mg, 30 mg, or 60 mg of brepocitinib once daily or placebo, advancing to 30 mg or 60 mg of brepocitinib once daily at week 16. The primary endpoint was the response rate according to the American College of Rheumatology criteria for 20% improvement (ACR20) in disease activity at week 16. Secondary endpoints included response rates according to the ACR50/ACR70 response criteria, 75% and 90% improvement in the Psoriasis Area and Severity Index (PASI75/PASI90) score, and minimal disease activity (MDA) at weeks 16 and 52. Adverse events were monitored throughout the study.ResultsOverall, 218 participants were randomized and treated. At week 16, the brepocitinib 30 mg and 60 mg once daily groups had significantly greater ACR20 response rates (66.7% [P = 0.0197] and 74.6% [P = 0.0006], respectively), versus the placebo group (43.3%), and significantly higher ACR50/ACR70, PASI75/PASI90, and MDA response rates. Response rates were maintained or improved through week 52. Adverse events were mostly mild/moderate; serious adverse events (15) in 12 participants (5.5%) included infections in 6 participants (2.8%) in the brepocitinib 30 mg and 60 mg once daily groups. No major adverse cardiovascular events or deaths occurred.ConclusionTreatment with brepocitinib at dosages of 30 mg and 60 mg once daily was superior to placebo at reducing signs and symptoms of PsA. Brepocitinib was generally well tolerated throughout the 52‐week study, with a safety profile consistent with those found in other brepocitinib clinical trials.
Annals of the rheumatic diseases · 2024
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Obesity research & clinical practice · 2026 · Journal Article
Lee JP, Bahamdan A, Franklin J, Martin D, et al.
The Journal of hand surgery, European volume · 2026 · Journal Article
Acott TR, Martin DS, Smetana BS
Biomedicines · 2025 · Journal Article
Toledano E, López-Mesonero L, Martín-Vallejo J, Chacón CC, et al.
Respiratory medicine · 2025 · Journal Article
Harrison SL, Loughran KJ, Suri S, Franklin A, et al.
JPGN reports · 2025 · Journal Article
Alkhouri R, Wong C, Richards A, Martin D, et al.
The Journal of arthroplasty · 2025 · Journal Article
Garvin KL, Harrast JJ, Nelson CL, Jacobs JJ, et al.
Matrix biology : journal of the International Society for Matrix Biology · 2025 · Journal Article
de Groot R, Folgado PB, Yamamoto K, Martin DR, et al.
Patient education and counseling · 2024 · Journal Article
Skidmore N, Ryan CG, Mankelow J, Martin D
The New England journal of medicine · 2024 · Clinical Study
Oikonomou V, Smith G, Constantine GM, Schmitt MM, et al.
Cureus · 2023 · Case Reports
Martin D, Toups CA, Loghmani A, Ford B, et al.
Therapeutic advances in musculoskeletal disease · 2023 · Journal Article
FitzGerald O, Behrens F, Barton A, Bertheussen H, et al.
Research involvement and engagement · 2023 · Letter
Harrison SL, Lawrence J, Suri S, Rapley T, et al.
Systematic reviews · 2025 · Journal Article
Monteiro AM, Schneider A, Encarnação S, Forte P, et al.
Digital health · 2025 · Journal Article
Deegan O, Riain EO, Martin D, Yoshitani M, et al.
Musculoskeletal science & practice · 2024 · Journal Article
Capsey M, Ryan C, Mankelow J, Martin D
Systematic reviews · 2025 · Journal Article
Monteiro AM, Schneider A, Encarnação S, Forte P, et al.
Clinical rehabilitation · 2023 · Systematic Review
Bradford C, Martin D, J Loughran K, Robertson N, et al.
Journal of integrative and complementary medicine · 2023 · Systematic Review
Ploesser M, Martin D
Annals of the rheumatic diseases · 2026 · Journal Article
Pranzatelli TJF, Perez P, Ku A, Matuck B, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Gupta S, Yamada E, Nakamura H, Perez P, et al.
Research square · 2024 · Journal Article
Pranzatelli TJF, Perez P, Ku A, Matuck B, et al.
Systematic reviews · 2025 · Journal Article
Monteiro AM, Schneider A, Encarnação S, Forte P, et al.
BMJ open · 2023 · Journal Article
Courel-Ibáñez J, Estévez-López F, Hughes C, Adams N, et al.
Archives of rehabilitation research and clinical translation · 2023 · Journal Article
Fullen BM, Wittink H, De Groef A, Hoegh M, et al.
Systematic reviews · 2025 · Journal Article
Monteiro AM, Schneider A, Encarnação S, Forte P, et al.
BMJ open · 2025 · Journal Article
Oatway S, Martin D, Graham A, Batterham A, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2023 · Clinical Trial, Phase II
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, et al.
Cureus · 2024 · Case Reports
Lane J, Read JM, Rahmany Z, Reely K, et al.
Frontiers in medicine · 2026 · Journal Article
Llamas-Ramos R, Llamas-Ramos I, Alvarado-Omenat JJ, Toledano E, et al.
RMD open · 2022 · Randomized Controlled Trial
Weitz JI, Szekanecz Z, Charles-Schoeman C, Vranic I, et al.
Physiotherapy · 2023 · Journal Article
Jess MA, Ryan C, Wellburn S, Atkinson G, et al.
Arthritis research & therapy · 2024 · Journal Article
Cohen S, Beebe JS, Chindalore V, Guan S, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2023 · Clinical Trial, Phase II
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, et al.
Bone & joint open · 2026 · Journal Article
Clement ND, Martin DH, Mason T, Simpson PMS
Biomedicines · 2026 · Journal Article
Hernández-Mezquita MA, Toledano E, Queiró R, Martín-Vallejo J, et al.
Effects of education to facilitate knowledge about chronic pain for adults: a systematic review with meta-analysis
Abstract Background Chronic pain can contribute to disability, depression, anxiety, sleep disturbances, poor quality of life and increased health care costs, with close to 20Â % of the adult population in Europe reportin
Supplemental Material - Emergency department use by people with back pain: An investigation
Supplemental Material for Emergency department use by people with back pain: An investigation by Matt Capsey, Cormac Ryan, Jagjit Mankelow, Jenny Alexanders and Denis Martin in British Journal of Pain
Emergency department use by people with back pain: An investigation
BackgroundDemand on emergency departments (EDs) is rising, at least in part due to patients with conditions suitable for management in primary care. Pain experienced in the back region is a common reason for patients to
Mechanistic emergence : different properties, different levels, same thing! ; a commentary on Carl F. Craver
An exploration of primary care healthcare professionals’ understanding of pain and pain management following a brief pain science education
Abstract Background Persistent pain is a leading cause of disability worldwide yet implementation of clinical guidelines that recommend a biopsychosocial approach remains a challenge in clinical practise. Limited pain un
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Clinical rehabilitation · 2023 · Systematic Review
Bradford C, Martin D, J Loughran K, Robertson N, et al.
Journal of integrative and complementary medicine · 2023 · Systematic Review
Ploesser M, Martin D
Respiratory medicine · 2023 · Systematic Review
Morris JR, Harrison SL, Robinson J, Martin D, et al.
Respiratory medicine · 2023 · Systematic Review
Morris JR, Harrison SL, Robinson J, Martin D, et al.
medRxiv : the preprint server for health sciences · 2023 · Preprint
Gupta S, Yamada E, Nakamura H, Perez P, et al.